keyword
https://read.qxmd.com/read/38651109/response-assessment-of-gbm-during-immunotherapy-by-delayed-contrast-treatment-response-assessment-maps
#1
JOURNAL ARTICLE
Valeria Cuccarini, Filippo Savoldi, Yael Mardor, David Last, Serena Pellegatta, Federica Mazzi, Maria Grazia Bruzzone, Elena Anghileri, Bianca Pollo, Luisa Maddaloni, Camilla Russo, Elisa Bocchi, Valentina Pinzi, Marica Eoli, Domenico Aquino
INTRODUCTION: Assessing the treatment response of glioblastoma multiforme during immunotherapy (IT) is an open issue. Treatment response assessment maps (TRAMs) might help distinguish true tumor progression (TTP) and pseudoprogression (PsP) in this setting. METHODS: We recruited 16 naïve glioblastoma patients enrolled in a phase II trial consisting of the Stupp protocol (a standardized treatment for glioblastoma involving combined radiotherapy and chemotherapy with temozolomide, followed by adjuvant temozolomide) plus IT with dendritic cells...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38650980/the-trogocytosis-of-neutrophils-on-initial-transplanted-tumor-in-mice
#2
JOURNAL ARTICLE
Mengru Zhu, Shengnan Wang, Kuo Qu, Feiyu Lu, Mengyuan Kou, Yunpeng Yao, Tong Zhu, Yongli Yu, Liying Wang, Chaoying Yan
The role of neutrophils in tumor initiation stage is rarely reported because of the lack of suitable models. We found that neutrophils recruited in early tumor nodules induced by subcutaneous inoculation of B16 melanoma cells were able to attack tumor cells by trogocytosis. The anti-tumor immunotherapy like peritoneal injection with TLR9 agonist CpG oligodeoxynucleotide combined with transforming growth factor β2 inhibitor TIO3 could increase the trogocytic neutrophils in the nodules, as well as CD8+ T cells, natural killer (NK) cells, and their interferon-γ production...
May 17, 2024: IScience
https://read.qxmd.com/read/38641734/single-cell-multiomic-dissection-of-response-and-resistance-to-chimeric-antigen-receptor-t-cells-against-bcma-in-relapsed-multiple-myeloma
#3
JOURNAL ARTICLE
Michael Rade, Nora Grieb, Ronald Weiss, Jaren Sia, Luise Fischer, Patrick Born, Andreas Boldt, Stephan Fricke, Paul Franz, Jonathan Scolnick, Lakshmi Venkatraman, Stacy Xu, Christina Kloetzer, Simone Heyn, Anne Sophie Kubasch, Ronny Baber, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Jule Ussmann, Birthe Schetschorke, Saskia Hell, Sebastian Schwind, Klaus H Metzeler, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Kristin Reiche, Vladan Vucinic, Maximilian Merz
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis...
April 19, 2024: Nature Cancer
https://read.qxmd.com/read/38641123/hierarchical-cluster-analysis-and-nonlinear-mixed-effects-modelling-for-candidate-biomarker-detection-in-preclinical-models-of-cancer
#4
JOURNAL ARTICLE
David Hodson, Hitesh Mistry, James Yates, Sofia Guzzetti, Michael Davies, Leon Aarons, Kayode Ogungbenro
BACKGROUND: Preclinical models of cancer can be of translational benefit when assessing how different biomarkers are regulated in response to particular treatments. Detection of molecular biomarkers in preclinical models of cancer is difficult due inter-animal variability in responses, combined with limited accessibility of longitudinal data. METHODS: Nonlinear mixed-effects modelling (NLME) was used to analyse tumour growth data based on expected tumour growth rates observed 7 days after initial doses (DD7) of Radiotherapy (RT) and Combination of RT with DNA Damage Response Inhibitors (DDRi)...
April 17, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38639407/dynamic-hybrid-module-driven-nk-cell-stimulation-and-release-for-tumor-immunotherapy
#5
JOURNAL ARTICLE
Deyan Jiao, Min Hao, Renhui Sun, Xiaolei Ren, Yanfei Wei, Miaomiao Ding, Xuetian Yue, Zhuanchang Wu, Chunyang Li, Lifen Gao, Chunhong Ma, Yuanhua Sang, Xiaohong Liang, Hong Liu
Natural killer (NK) cells have become a powerful candidate for adoptive tumor immunotherapy, while their therapeutic efficacy in solid tumors remains unsatisfactory. Here, we developed a hybrid module with an injectable hydrogel and hydroxyapatite (HAp) nanobelts for the controlled delivery of NK cells to enhance the therapy of solid tumors. Surface-functionalized HAp nanobelts modified with agonistic antibodies against NKG2D and 4-1BB and cytokines IL-2 and IL-21 support survival and dynamic activation. Thus, the HAp-modified chitosan (CS) thermos-sensitive hydrogel not only improved the retention of NK cells for more than 20 days in vivo but also increased NK cell function by more than one-fold...
April 19, 2024: Nano Letters
https://read.qxmd.com/read/38638431/therapeutic-potential-of-interleukin-21-in-cancer
#6
REVIEW
Gheorghita Isvoranu, Marioara Chiritoiu-Butnaru
Interleukin-21 (IL-21) is an immunostimulatory cytokine which belongs to the common gamma-chain family of cytokines. It plays an import role in the development, differentiation, proliferation, and activation of immune cells, in particular T and natural killer (NK) cells. Since its discovery in 2000, IL-21 has been shown to regulate both adaptive and immune responses associates with key role in antiviral and antitumor responses. Recent advances indicate IL-21 as a promising target for cancer treatment and encouraging results were obtained in preclinical studies which investigated the potency of IL-21 alone or in combination with other therapies, including monoclonal antibodies, checkpoint inhibitory molecules, oncolytic virotherapy, and adoptive cell transfer...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38637666/fat-matters-for-natural-killer-cell-activity
#7
JOURNAL ARTICLE
Pamela Wong, Todd A Fehniger
No abstract text is available yet for this article.
April 18, 2024: Nature Immunology
https://read.qxmd.com/read/38637625/dysfunctional-natural-killer-cells-can-be-reprogrammed-to-regain-anti-tumor-activity
#8
JOURNAL ARTICLE
Batel Sabag, Abhishek Puthenveetil, Moria Levy, Noah Joseph, Tirtza Doniger, Orly Yaron, Sarit Karako-Lampert, Itay Lazar, Fatima Awwad, Shahar Ashkenazi, Mira Barda-Saad
Natural killer (NK) cells are critical to the innate immune system, as they recognize antigens without prior sensitization, and contribute to the control and clearance of viral infections and cancer. However, a significant proportion of NK cells in mice and humans do not express classical inhibitory receptors during their education process and are rendered naturally "anergic", i.e., exhibiting reduced effector functions. The molecular events leading to NK cell anergy as well as their relation to those underlying NK cell exhaustion that arises from overstimulation in chronic conditions, remain unknown...
April 18, 2024: EMBO Journal
https://read.qxmd.com/read/38637557/induction-of-nk-cell-reactivity-against-acute-myeloid-leukemia-by-fc-optimized-cd276-b7-h3-antibody
#9
JOURNAL ARTICLE
Sylwia A Stefańczyk, Ilona Hagelstein, Martina S Lutz, Stefanie Müller, Samuel J Holzmayer, Grace Jarjour, Latifa Zekri, Jonas S Heitmann, Helmut R Salih, Melanie Märklin
Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal antibodies (mAbs) engaging natural killer (NK) cells via antibody-dependent cellular cytotoxicity (ADCC) hold promise in cancer therapy, almost none have received clinical approval for AML, so far. Recently, CD276 (B7-H3) has emerged as a promising target for AML immunotherapy, due to its high expression on leukemic blasts of AML patients. Here, we present the preclinical development of the Fc-optimized CD276 mAb 8H8_SDIE with enhanced CD16 affinity...
April 18, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38635551/enhanced-cytotoxic-activity-of-natural-killer-cells-from-increased-calcium-influx-induced-by-electrical-stimulation
#10
JOURNAL ARTICLE
Minseon Lee, Soonjo Kwon
Natural killer (NK) cells play a crucial role in immunosurveillance independent of antigen presentation, which is regulated by signal balance via activating and inhibitory receptors. The anti-tumor activity of NK cells is largely dependent on signaling from target recognition to cytolytic degranulation; however, the underlying mechanism remains unclear, and NK cell cytotoxicity is readily impaired by tumor cells. Understanding the activation mechanism is necessary to overcome the immune evasion mechanism, which remains an obstacle in immunotherapy...
2024: PloS One
https://read.qxmd.com/read/38634972/exploring-natural-killer-cell-related-biomarkers-in-multiple-myeloma-a-novel-nature-killer-cell-related-model-predicting-prognosis-and-immunotherapy-response-using-single-cell-study
#11
JOURNAL ARTICLE
Jing Zhao, Xiaoning Wang, Huachao Zhu, Suhua Wei, Hailing Zhang, Le Ma, Wenjuan Zhu
BACKGROUND: Natural killer cells (NKs) may be involved in multiple myeloma (MM) progression. The present study elucidated the correlation between NKs and the progression of MM using single-cell binding transcriptome probes to identify NK cell-related biomarkers. METHODS: Single-cell analysis was performed including cell and subtype annotation, cell communication, and pseudotime analysis. Hallmark pathway enrichment analysis of NKs and NKs-related differentially expressed genes (DEGs) were conducted using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction (PPI) networks...
April 18, 2024: Clinical and Experimental Medicine
https://read.qxmd.com/read/38631708/preclinical-evaluation-and-first-in-dog-clinical-trials-of-pbmc-expanded-natural-killer-cells-for-adoptive-immunotherapy-in-dogs-with-cancer
#12
JOURNAL ARTICLE
Aryana M Razmara, Lauren E Farley, Rayna M Harris, Sean J Judge, Marshall Lammers, Khurshid R Iranpur, Eric G Johnson, Cordelia Dunai, William J Murphy, C Titus Brown, Robert B Rebhun, Michael S Kent, Robert J Canter
BACKGROUND: Natural killer (NK) cells are cytotoxic cells capable of recognizing heterogeneous cancer targets without prior sensitization, making them promising prospects for use in cellular immunotherapy. Companion dogs develop spontaneous cancers in the context of an intact immune system, representing a valid cancer immunotherapy model. Previously, CD5 depletion of peripheral blood mononuclear cells (PBMCs) was used in dogs to isolate a CD5dim -expressing NK subset prior to co-culture with an irradiated feeder line, but this can limit the yield of the final NK product...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38629075/natural-killer-t-cells-in-allergic-asthma-implications-for-the-development-of-novel-immunotherapeutical-strategies
#13
REVIEW
Cristián Gutiérrez-Vera, Richard García-Betancourt, Pablo A Palacios, Marioly Müller, David A Montero, Carlos Verdugo, Francisca Ortiz, Felipe Simon, Alexis M Kalergis, Pablo A González, Noemi A Saavedra-Avila, Steven A Porcelli, Leandro J Carreño
Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38626547/a-review-mechanisms-and-molecular-pathways-of-signaling-lymphocytic-activation-molecule-family-3-slamf3-in-immune-modulation-and-therapeutic-prospects
#14
REVIEW
Tong Zhou, Yanjie Guan, Lin Sun, Wentao Liu
The signaling lymphocytic activation molecule (SLAM) family participates in the modulation of various innate and adaptive immune responses. SLAM family (SLAMF) receptors include nine transmembrane glycoproteins, of which SLAMF3 (also known as CD229 or Ly9) has important roles in the modulation of immune responses, from the fundamental activation and suppression of immune cells to the regulation of intricate immune networks. SLAMF3 is mainly expressed in immune cells, such as T, B, and natural killer cells. It has a unique molecular structure, including four immunoglobulin-like domains in the extracellular domain and two immunoreceptor tyrosine-based signaling motifs in the intracellular structural domains...
April 15, 2024: International Immunopharmacology
https://read.qxmd.com/read/38622654/immunotherapy-with-an-antibody-against-cd1d-modulates-neuroinflammation-in-an-%C3%AE-synuclein-transgenic-model-of-lewy-body-like-disease
#15
JOURNAL ARTICLE
Michiyo Iba, Somin Kwon, Changyoun Kim, Marcell Szabo, Liam Horan-Portelance, Maria Lopez-Ocasio, Pradeep Dagur, Cassia Overk, Robert A Rissman, Eliezer Masliah
The neuroinflammatory process in synucleinopathies of the aging population such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) involves microglial activation as well as infiltration of the CNS by T cells and natural killer T cells (NKTs). To evaluate the potential of targeting NKT cells to modulate neuroinflammation, we treated α-syn transgenic (tg) mice (e.g.: Thy1 promoter line 61) with an antibody against CD1d, which is a glycoprotein expressed in antigen presenting cells (APCs). CD1d-presented lipid antigens activate NKT cells through the interaction with T cell receptor in NKTs, resulting in the production of cytokines...
April 15, 2024: Journal of Neuroinflammation
https://read.qxmd.com/read/38619967/functional-genomics-identifies-n-acetyllactosamine-extension-of-complex-n-glycans-as-a-mechanism-to-evade-lysis-by-natural-killer-cells
#16
JOURNAL ARTICLE
Xiaoxuan Zhuang, James Woods, Yanlong Ji, Sebastian Scheich, Fei Mo, Sumati Rajagopalan, Zana A Coulibaly, Matthias Voss, Henning Urlaub, Louis M Staudt, Kuan-Ting Pan, Eric O Long
Natural killer (NK) cells are primary defenders against cancer precursors, but cancer cells can persist by evading immune surveillance. To investigate the genetic mechanisms underlying this evasion, we perform a genome-wide CRISPR screen using B lymphoblastoid cells. SPPL3, a peptidase that cleaves glycosyltransferases in the Golgi, emerges as a top hit facilitating evasion from NK cytotoxicity. SPPL3-deleted cells accumulate glycosyltransferases and complex N-glycans, disrupting not only binding of ligands to NK receptors but also binding of rituximab, a CD20 antibody approved for treating B cell cancers...
April 14, 2024: Cell Reports
https://read.qxmd.com/read/38618731/role-of-natural-killer-cells-as-cell-based-immunotherapy-in-oral-tumor-eradication-and-differentiation-both-in-vivo-and-in-vitro
#17
JOURNAL ARTICLE
Kawaljit Kaur, Anahid Jewett
Despite advancements in the field of cancer therapeutics, the five-year survival rate remains low in oral cancer patients. Therefore, the effective therapeutics are needed against oral cancer. Also, several studies including ours, have shown severely suppressed function and number of NK cells in oral cancer patients. In this review, we discuss the approach to inhibit the tumor growth and metastasis by direct killing or NK cell-mediated tumor differentiation. This review also provides an overview on supercharging NK cells using osteoclasts and probiotic bacteria, and their efficacy as cancer immunotherapeutic in humanized-BLT mice...
2024: Critical Reviews in Immunology
https://read.qxmd.com/read/38618730/current-and-future-states-of-natural-killer-cell-based-immunotherapy-in-hepatocellular-carcinoma
#18
JOURNAL ARTICLE
Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven S Raman, Anahid Jewett, Jason Chiang
Natural killer (NK) cells are innate lymphoid cells that exhibit high levels of cytotoxicity against NK-specific targets. NK cells also produce various cytokines, and interact with T cells, B cells, and dendritic cells to effectively serve as frontliners of the innate immune system. Produce various cytokines, and interact with T cells, B cells, and dendritic cells to effectively serve as frontliners of the innate immune system. Moreover, NK cells constitute the second most common immune cell in the liver. These properties have drawn significant attention towards leveraging NK cells in treating liver cancer, especially hepatocellular carcinoma (HCC), which accounts for 75% of all primary liver cancer and is the fourth leading cause of cancer-related death worldwide...
2024: Critical Reviews in Immunology
https://read.qxmd.com/read/38618203/camrelizumab-chemotherapy-and-apatinib-in-the-neoadjuvant-treatment-of-resectable-oesophageal-squamous-cell-carcinoma-a-single-arm-phase-2-trial
#19
JOURNAL ARTICLE
Zixiang Wu, Chuanqiang Wu, Jing Zhao, Cong Wu, Haixian Peng, Qi Wang, Rui Bai, Xuefeng Fang, Hong He, Hong Shen, Ming Wu
BACKGROUND: In resectable oesophageal squamous cell carcinoma (ESCC), the efficacy of camrelizumab combined with chemotherapy and apatinib followed by minimally invasive oesophagectomy is not clear. We aimed to fill this knowledge gap. METHODS: This investigator-initiated, single-arm, prospective, phase 2 trial was performed at the Second Affiliated Hospital of Zhejiang University, China. Patients (aged 18-75 years) who were histologically or cytologically diagnosed with ESCC were deemed suitable to participate in this trial...
May 2024: EClinicalMedicine
https://read.qxmd.com/read/38615584/efficacy-and-safety-of-cell-based-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-nasopharyngeal-carcinoma-a-systematic-review-and-meta-analysis
#20
JOURNAL ARTICLE
Brian Sheng Yep Yeo, Rachel Siying Lee, Nicholas E-Kai Lim, Ethan Tan, Isabelle Jia Hui Jang, Han Chong Toh, Chwee Ming Lim
BACKGROUND: Recurrent/Metastatic Nasopharyngeal Carcinoma (RM-NPC) remains difficult to treat and contributes to considerable mortality. The first-line treatment for RM-NPC is Gemcitabine and Cisplatin and second-line treatment options differ. The endemic variant of NPC is associated with Epstein-Barr Virus (EBV). Therefore, Cell-based Immunotherapy (CBI) targeting EBV-specific RM-NPC may be effective. METHODS: We systematically searched PubMed, Embase and the Cochrane Library for randomised or observational studies investigating the efficacy and safety of CBI in the treatment of RM-NPC...
April 13, 2024: Oral Oncology
keyword
keyword
33186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.